Aims Liver hepatocellular carcinoma (LIHC) is the main manifestation of primary liver
cancer, with low survival rate and poor prognosis. Medical decision-making process of LIHC …

Background. As the most common hepatic malignancy, hepatocellular carcinoma (HCC) has
a high incidence; therefore, in this paper, the immune‐related genes were sought as …

Hepatocellular carcinoma (HCC) is a typical inflammation‑driven cancer. Chronically
unresolved inflammation may remodel the immunosuppressive tumor microenvironment …

Objective. Dysregulation of cell cycle progression (CCP) is one of the hallmarks of cancer.
Here, our study is aimed at developing a CCP‐derived gene signature for predicting high …

Liver hepatocellular carcinoma (LIHC) is a highly lethal malignant tumor originating from the
digestive system, which is a serious threat to human health. In recent years, immunotherapy …

Abstract Treatment is challenging due to the heterogeneity of hepatocellular carcinoma
(HCC). Chromatin regulators (CRs) are important in epigenetics and are closely associated …

Background Although the tumour immune microenvironment is known to significantly
influence immunotherapy outcomes, its association with changes in gene expression …

Background: Although current immunotherapies have achieved some successes for
hepatocellular carcinoma (HCC) patients, their benefits are limited for most HCC patients …

Introduction Hepatocellular carcinoma (HCC) is the most common form of primary liver
cancer. It is the fourth leading cause of cancer-related death worldwide. Deregulation of the …

Hepatocellular carcinoma (HCC) is a high mortality malignancy and the second leading
cause of cancer-related deaths. Because the immune system plays a dual role by assisting …